Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment

Critical Reviews in Toxicology

Volumn 27, Issue 5, 1997, Pages 495-537

  Knasmüller, Siegfried ^a   Parzefall, Wolfram ^a   Helma, Christoph ^a   Kassie, Fekadu ^a   Ecker, Sonja ^a   Schulte Hermann, Rolf ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aneuploidy; Carcinogenicity; Cytochrome P 450; Genotoxicity; Griseofulvin; Liver; Mallory bodies; P glycoprotein; Porphyria; Teratogenicity

Indexed keywords

GRISEOFULVIN; PORPHYRIN; THYROXINE;

CARCINOGENICITY; CELL DAMAGE; GENOTOXICITY; HUMAN; LIVER CELL CARCINOMA; MALLORY BODY; MICROTUBULE ASSEMBLY; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; REPRODUCTIVE TOXICITY; REVIEW; SOMATIC CELL; TERATOGENICITY; THYROID TUMOR;

EID: 0030865830     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408449709078444     Document Type: Review

References (263)

1. Aardema H. J., Curry P. T., Gudi R. and Putman D. L., Griseofulvin induced structural and numerical chromosomal aberrations in vitro and in vivo. Env. Molec. Mutagen., 27, Suppl. 27, 1 (abstract), 1996
2. Adamson, R. H. and Sieber, S. M., Carcinogenic potential of drugs, J. Environm. Pathol. Toxicol. Oncol., 3/4, 377-385, 1981.
3. Adler, I. D. and Brewen, J. G., Effects of chemicals on chromosome aberrations production in male and female germ cells, in A. Hollaender (Ed.), Chemical Mutagens - Principles and Methods for their Detection Vol. VII, 1-35, 1982.
4. Albertini, S., Brunner, M. and Würgler, F., Analysis of the six additional chemicals for in vitro analysis of the European economic communities (EEC) aneuploidy programme using Saccharomyces Cervisiae D 61 M and the in vitro porcine brain tubulin assembly assay, Env. Molec. Mutagen., 21, 180-192, 1993.
5. Amacher, D. E. and Zelljadt, I., The morphological transformation of Syrian hamster embryo cells by chemicals reportedly nonmutagenic to Salmonella typhimurium, Carcinogenesis, 4, 291-296, 1983.
6. Anthony, H. M. and Kenny, T. E., Drugs in the etiology of cancer. A retrospective study, Int. J. Epidem., 11, 336-344, 1982.
7. Atkinson, R. M., Bedford, C., Child, K. J. and Tomich, E. G., Effect of particle size on blood Griseofulvin levels in man, Nature, 193, 588-589, 1962.
8. Aujezdska, A., Effect of Griseofulvin on mouse fetal skeleton, Cesk. Hyg. 23, 5-21, 1978.
9. Axelson O., A review of porphyria and cancer and the missing link with human exposure to hexachlorbenzene, in Hexachlorbenzene: Proceedings of an International Symposium, Morris C. R. and Cabral J. R. P., Eds., IARC Sci. Publ. Vol. 77, Lyon 1985a, 585-589.
10. Axelson O., Hardell L., Saracci R. and Simontano L., Epidemiological studies in porphyrias in Hexachlorbenzene: Proceedings of an International Symposium, Morris C. R. and Cabral J. R. P., Eds., IARC Sci. Publ. Vol. 77, Lyon pp. 1985b, 593-594.
11. Barich, L. L., Schwarz, J. and Barich, D., Oral Griseofulvin: a cocarcinogenic agent to methylcholanthrene induced cutaneous tumors. Cancer Res., 22, 53-55, 1962.
12. Barich, L. L., Schwarz, J., Barich, D. J. and Horowitz, M. G., Toxic liver damage in mice after prolonged intake of elevated doses of Griseofulvin, Antibiot. Chemother., 11, 566-568, 1961.
13. Barrett, W. and Bianchine, J. R., The bioavailability of ultramicrosize Griseofulvin tablets in man, Curr. Ther. Res., 18, 501-509, 1975.
14. Bedford, C., Busfield, D., Child, K. J., McGregor, I., Sutherland, P. and Tomich, E. G., Studies on the biological disposition of Griseofulvin an oral antifungal agent, Arch. Dermatol., 81, 735-745, 1960.
15. Benedict, W. F., Murphree, A. L., Banerjee, A., Spina, C. A., Sparkes, M. C. and Sparkes, R. S., Patient with chromosome 13 deletion: evidence that the retinoblastoma gene is a recessive cancer gene, Science, 219, 973-975, 1983.
16. Bengtsson, N. O. and Hardell, L., Porphyrias, porphyrins and hepatocellular cancer, Br. J. Cancer, 54, 115-117, 1986.
17. Bennett, J. E., Antimicrobial agents. In: Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 8th. Edition, A. Gilman, T.W. Rall, A.S. Nies and P. Taylor, Eds., Macmillan, 1173-1174, 1990.
18. Berman, A. and Franklin, R.L.; Precipitation of acute intermittent porphyria by griseofulvin therapy, J. Am. Med. Assoc., 192, 1005-1007, 1965.
19. Berman, J. and Brown, A., Incidence of hepatoma in porphyria cutanea tarda, Rev. Czech. Med., 8, 290-295, 1962.
20. Beukeveld G.J., Walthers B. G., vanSaene J.J.M., deHaan T.H.I.J., Ruyter-Buitenhuis L.W. and van Saene R.H.F., Patterns of porphyrin exceretion in feces as determined by liquid chromatography: reference values and the effect of flora suppression. Clin. Chem., 31, 2164-2170, 1987
21. Beukeveld, G. J., In 't Veld, G., Havinga, R., Groen, A. K., Wolthers, B. G., and Kuipers, F., Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport, J. Hepatol, 24, 343-52, 1996.
22. Blacow, N. W., Drug information centres: a hospital pharmacist's view, Proc. R. Soc. Med., 70, 250-2, 1977.
23. Borenfreund, E., De Harven, E. and Garra, L., Mallory body like abnormalities in carcinomas induced by cultured transformed liver cells, Hepatology, 1, 408-415, 1981.
24. Borenfreund, E., Higgins, P.J. and Bendich, A., In vitro - in vivo rat liver carcinogenesis: modifications in protein synthesis and ultrastructure, Ann. N.Y. Acad. Sci., 349, 352-357, 1980.
25. Borenfreund, E., Higgins, P.J., Steinglass, M. and Bendich, A., Carcinogen induced abnormalities in rat liver cells and their modification by chemical agents, Canc. Res., 39, 800-807, 1979.
26. Brady, A. M. and Lock, E. A., Inhibition of ferrochelatase and accumulation of porphyrins in mouse hepatocyte cultures exposed to porphyrinogenic chemicals., Arch-Toxicol, 66, 175-181, 1992.
27. Brossi, A., Baumann, M., Gerecke, M. and Kyburz, E., Totalsynthese von Griseofulvin, Helv. Chim. Acta, 43, 1444-1447, 1960.
28. Bursch, W., Lauer, B., Timmermann-Trosiener, I., Barthel, G., Schuppler, J., and Schulte-Hermann R., Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters, Carcinogenesis, 5, 453-458, 1984.
29. Bursch, W., Oberhammer, F. and Schulte-Hermann, R., Cell death by apoptosis and its protective role against disease, Trends in Pharmacological Sciences, 13, 245-251, 1992.
30. Cabaral, F., Sobel, M.E. and Gottesman, M.M., CHO-mutants resistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin, Cell, 20, 29-36, 1980.
31. Cabral, J.R.P., Shubik, P., Mollner, T. and Raitano, F., Carcinogenic activity of hexachlorobenzene, Nature, 269, 510-511, 1977.
32. Cadrin, M., Kawahara, H., Ohta, M., Katsuma, Y., Marceau, N. and French, S.W., Mallory bodies in hepatomas and hyperplastic nodules: In vivo and in vitro studies, In: Stevenson, D.E., Popp, J.A., Ward, J.M., McClain, R.M., Slaga, T.J., Pilot, H.C., Eds. Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons, Alan R. Liss., New York, 231-248, 1990.
33. Cantoni, L., Di Padova, C., Rovagnati, P., Ruggieri, R., Dal Fiume D. and Tritapepe, R., Bile secretion and liver microsomal mixed function oxidase system in mice with griseofulvin-induced hepatic protoporphyria, Toxicology, 27, 27-39, 1983.
34. Carrano, A. V. and Thompson, L. H., Sister chromatid exchange and gene mutation., Cytogenet-Cell-Genet. 33, 57-61, 1982.
35. Cavenee, W.K., Dryja, T.P., Phillips, R.A., Benedict, W.F., Goldbart, R., Gallie, B.L., Murphree, A.L., Strong, L.C. and White, R.L., Expression of recessive alleles by chromosomal mechanisms in retinoblastoma, Nature, 305, 779-784, 1983.
36. Cerutti, P.A., Prooxidant states and tumor promotion, Science, 227, 375-381, 1985.
37. Chen, H., Rupa, D.S., Tomar, R. and Eastmond, D.A., Chromosomal loss and breakage in mouse bone marrow and spleen cells exposed to benzene in vivo., Cancer-Res, 54, 3533-9, 1994.
38. Chiou, W.L. and Riegleman, S., Absorption characteristics of solid dispersed and micronized griseofulvin in man, J. Pharm. Sci., 60 (9), 1376-1380, 1971.
39. Chiprut, R.O., Viteri, A., Jamroz, C. and Dyck, W.P., Intrahepatic cholestasis after griseofulvin administration, Gastroenterology, 70, 1141-43, 1976.
40. Choi, S.W., Han, J.H., Lim, K.T. Cho, H.M., Chung, K.W., Sun, H.S., Park, D.H., Kim, B.S. and Seo, E.J., Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin, J. Kor. Med. Sci., 6, 146-156, 1991.
41. Choy, W.H. and Ts'o, P.O.P., Induction of heteroploidy in diploid cells using antimitotic agents, J. Cell Biol., 91, 383a, 1981.
42. Cohen, S.M. and Ellwein, L.B., Genetic errors, cell proliferation, and carcinogenesis, Cancer Research, 51, 6493-6505, 1991.
43. Cole, S. P. and Marks, G. S., Ferrochelatase and N-alkylated porphyrins, Mol. Cell. Biochem., 64, 127-137, 1984.
44. Cole, S. P., Massey, T. E., Marks, G. S. and Racz, W. J., Effects of porphyrin-inducing drugs on ferrochelatase activity in isolated mouse hepatocytes., Can. J. Physiol. Pharmacol., 59, 1155-1158, 1981.
45. Columbano, A., Dessi, S., Ledda Columbano, G. M., Chiodino, C., Coni, P., Pani, P., and Rao, K. N., HMP-shunt and cholesterol metabolism in experimental models involving normal and preneoplastic liver growth., Toxicol. Pathol, 15, 43-50, 1987.
46. Cortes, J.M., Oliva, H., Paradines, F.J. and Hernandez-Guio, C., The pathology of the liver in porphyria cutanea tarda, Histopathology, 4, 471-485, 1980.
47. Cripps D.J., Porphyria: genetic and aquired, in Hexachlorbenzene: Proceedings of an International Symposium. Morris C.R. Cabral J.R.P., Eds., IARC Sci. Publ. Vol. 77, Lyon 1985, 549-566.
48. Cripps, D.J., Liem, H.H. and Muller-Eberhard, U., Griseofulvin causing hyper-hemopexinemia and hepatic proliferation in mice: an in vivo and in vitro study, J. Inv. Dermatol., 68 (2), 82-87, 1977.
49. Crossin, K.L. and Carney D.H., Evidence that microtubule depolymerisation early in the cell cycle is sufficient to initiate DNA-synthesis, Cell, 23, 61-78, 1981.
50. Cullen, S.I. and Catalano, P.M., Griseofulvin - warfarin Antagonism, J. Am. Med. Assoc., 199, 150-151, 1967.
51. Curry, P.T., Reed, R. N., Martino, R.M. and Kitchin, R.M., Induction of sister chromatid exchanges in vivo in mice by the mycotoxins sterigmatocystin and griseofulvin, Mut. Res., 137, 111-115, 1984.
52. Daya-Grosjean, L., Sarasin, A. and Monier, R., Effect of tumor promotion on soft agar growth in Swiss 3T3 cells infected with SV40 ts-A mutants. Carcinogenesis, 3 (7), 833-835, 1982.
53. De Brabander, M., Aerts, F., Van de Veire, R. and Borgers, M., Evidence against interconversion of microtubules and filaments, Nature, 253, 119-120, 1975.
54. De Carli, L. and Larizza, L., Griseofulvin, Mutat. Res., 195, 91-126, 1988.
55. De Matteis, F., Abritti, G. and Gibbs, A.H., Decreased liver activity of porphyrin-metal chelatase in hepatic porphyria caused by 3,5-diethoxy-carbonyl-1,4-dihydrochollidine. Studies on rats and mice, Biochem. J., 134, 717-727, 1973.
56. De Matteis, F., Donnelly, A.J. and Runge, W.J., The effect of prolonged administration of griseofulvin in mice with reference to sex differences, Cancer Res., 26, 721-726, 1966.
57. De Matteis, F. and Gibbs, A.H., Stimulation of the pathway of porphyrin synthesis in the liver of rats and mice by griseofulvin, 3,5-diethoxycarbonyl-1,4-dihydro-collidine and related drugs: evidence for two basically different mechanisms, Biochem. J., 146, 285-287, 1975.
58. De Matteis, F., Hypercholesterolaemia and liver enlargement in experimental hepatic porphyria, Biochem. J. 98, 230-250, 1966.
59. De Matteis, F. and Rimington, C., Disturbance of porphyrin metabolism caused by griseofulvin in mice, Brit. J. Dermatol., 75, 91-104, 1963.
60. Dehner, L.P. and Krivit, W., Griseofulvin therapy as a cause of lymphnode proliferation resembling malignant histiocytosis, Pediatric Res., 11, 470, 1977.
61. Denk, H. and Eckersdorfer, R., Colchicine induced Mallory body formation in the mouse, Lab. Invest. 36, 563, 1977.
62. Denk, H., Abdelfattah-Gad, M., Eckerstorfer, R. and Talcott, R.E., Microsomal mixed-function oxidase and activities of some related enzymes in hyperplastic nodules induced by long-term griseofulvin administration in mouse liver, Canc. Res., 40, 2568-2573, 1980.
63. Denk, H., Eckerstorfer, R., Gschnait, F., Konrad, K., and Wolff, K., Experimental induction of hepatocellular hyalin (Mallory bodies) in mice by griseofulvin treatment. 1. Light microscopic observation., Lab-Invest, 35, 377-82, 1976.
64. Denk, H., Franke, W., Dragosics, B. and Zeiler, I., Pathology of cytoskeleton of liver cells: Demonstration of Mallory bodies in murine and human hepatocytes by immunofluorescence microscopy using antibodies to cytokeratin polypeptides from hepatocytes, Hepatology, 1, 9-20, 1981a.
65. Denk, H., Gschnait, F. and Wolff, K., Hepatocellular hyalin (Mallory bodies) in long term griseofulvin treated mice: a new experimental model for the study of hyalin formation, Lab. Invest., 32, 773-776,1975.
66. Denk, H., Kalt, R., Abdelfattah-Gad, M. and Meyer, U.A., Effect of griseofulvin on 5-aminolevulinate synthase and on ferrochelatase in mouse liver neoplastic nodules, Canc. Res., 41, 1535-1538, 1981b.
67. Denk, H., Krepler, R., Lackinger, E., Artlieb, U. and Franke, W.W., Immunological and biochemical characterisation of the hepatin-related component of Malloy bodies: A pathological pattern of hepatocytic cytokeratins, Liver, 2, 165-175, 1982.
68. Diwan, B. A., Henneman, J. R., Rice, J. M., and Nims, R. W., Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene in rats at doses that cause maximal induction of CYP2B., Carcinogenesis, 17, 37-43, 1996.
69. Ellwein L.B. and Cohen S.H. The health risks of saccharin revisited, Crit. Rev. Toxicol., 20, 311-326, 1990.
70. El Mofty, M.M., Khudoley, V.V., Essawy, A.E. and Abdel-Kerim, H.M., Induction of hepatocellular carcinomas in the egyptian toad (Bufo regularis) by an antifungal drug (Griseofulvin), Oncology, 50, 267-269, 1993.
71. Epe, B., Harttig, U., Stopper, H. and Metzler, M., Covalent binding of reactive estrogen metabolites to microtubular protein as a possible mechanism of aneuploidy induction and neoplastic cell transformation., Environm. Health Perspect., 88, 123-7, 1990
72. Epstein, S.S., Andrea, J., Joshi, S. and Mantel, N. Hepatocarcinogenicity of griseofulvin following parenteral administration to infant mice, Cancer Res., 27, 1900-1906, 1967.
73. Epstein, S.S., Arnold, E., Andrea, J., Bass, W. and Bishop, Y., Detection of chemical mutagens by the dominant lethal assay in the mouse, Toxicol. Appl. Pharmacol., 23, 288-325, 1972.
74. Evans H.J., Human lymphocytes for the analysis of chromosome aberrations in mutagen tests. In Kilbey B.J., Legator M., Nichols W., and Ramel C., Eds. Handbook of Mutagenicity Test Procedures. 2nd ed., Elsevier, Amsterdam, 405-428, 1984
75. Faccini, J. M., Butler, W. R., Friedmann, J. C., Hess, R., Reznik, G. K., Ito, N., Hayashi, Y., and Williams, G. M., IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay, Experimental and Toxicologic Pathology, 44, 443-456, 1992.
76. Farber, E., Hepatocyte proliferation in stepwise development of experimental liver cell cancer, Digestive Diseases and Sciences, 36, 973-978, 1991.
77. Franke, W.W., Denk, H., Schmidt, E., Osborn, M. and Weber, K., Ultrastructural, biochemical, and immunological characterisation of Mallory bodies in livers of griseofulvin treated mice. Lab. Invest., 40, 207-220, 1979.
78. French S.W., Irie, T., Tazawa, J. and Benson, N.C., Electron microscopic study of hepatoma and hyperplastic nodules induced by griseofulvin in mice. Fed. Proc., 43, 3169, 1984.
79. French, S., Sim, J., Franks, K., Burbidge, E., Denton, T. and Caldwell, M., Alcoholic hepatitis, in Alcohol and the Liver, Fisher, M. and Rankin, J., Eds., Plenum Press, New York, 1977, 261-268.
80. Friedkin, M. and Rozengurt, E., The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors, Adv. Enz. Regul., 19, 39-59, 1981.
81. Fucic, A., Garaj Vrhovac, V., Skara, M. and Dimitrovic, B., X-rays, microwaves and vinyl chloride monomer: their clastogenic and aneugenic activity, using the micronucleus assay on human lymphocytes., Mutat. Res, 282, 265-71, 1992
82. Fujita, J., Yoshida, O., Sugawara, K. and Ito, Y., Enhanced expression of Epstein-Barr virus early antigen by agents in a lately infected human lymphoblastoid cell line, Experientia, 41, 372-373, 1985.
83. Gebhart, E., Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing., Hum-Genet, 58, 235-54, 1981.
84. Gerbracht, U., Bursch, W., Kraus, P., Putz, B., Reinacher M., Timmermann-Trosiener, I., and Schulte-Hermann, R., Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver, Carcinogenesis, 11, 617-624, 1990.
85. Goetz, H. and Reichberger, M., Ergebnisse einer Fragebogenaktion bei 1670 Dermatologen der Bundesrepublik Deutschland über Nebenwirkungen der Griseofulvintherapie, Hautartzt, 23, 485-492, 1972.
86. Goetz, H., Side effects of griseofulvin therapy after 12 years experience, Arch. Dermatol. Forsch., 244, 391-395, 1972.
87. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. A. Goodman Gilman, T.W. Rall, A.S. Nies, P. Eds. Taylor, Pergamon Press, New York, 1184, 1995
88. Griesbach, R.J., Schnabelrauch, L.S. and Sink, K.C. Griseofulvin-induced chromosome instability and reduction in a Petunia somatic hybrid. Journal of the American Society for Horticultural Science, 108, 714-716, 1983.
89. Grisham, L., Wilson, L. and Bensch, K., Antimitotic action of griseofulvin does not involve disruption of microtubules, Nature, 244, 294-296, 1973.
90. Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L. and Robertson, M. Identification and characterization of the familial adenomatous polyposis coli gene., Cell, 66, 589-600, 1991.
91. Grove, J.F., Griseofulvin, Q. Rev. Chem. Soc., 17, 1-19, 1963.
92. Gschnait, F., Konrad, K., Hönigsmann, H., Denk, H. and Wolff, K., Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals, J. Invest. Dermatol., 65, 290-299, 1975.
93. Gudi R., Poris S.K., Ritter A.P. and Putman D.L. Griseofulvin induced cell division abnormalities in Syrian hamster embryo cells. Environ. Mol. Mutagen., 27, Suppl.27, 26 (abstract), 1996
94. Gupta, R.S., Griseofulvin resistance mutation of Chinese hamster ovary cells that affects the apparent molecular weight of a 200 000 Dalton protein, Mol. Cell Biol., 4, 1761-1768, 1984.
95. Hägermark, Ö., Berlin, A., Walin, I. and Boreus, L.O., Plasma concentration of griseofulvin in healthy volunteers and patients treated for oxychomycosis, Acta Dermatovener., 56, 289-296, 1976.
96. Hard G.C. and Whyser J. Risk assessment of D-limonene: An example of male rat specific renal tumorigenesis. Crit.Rev.Toxicol., 24, 231-254, 1994
97. Hardell L., Aspects of primary liver cancer and its relation to porphyria cutanea trada and porphyria cutanea intermittens, in: Hexachlorbenzene: Proceedings of an International Symposium, Morris C.R. and Cabral J.R.P., Eds., IARC Sci.Publ. Vol.77, Lyon 1985, 591-592.
98. Hazan, R., Denk, H., Franke, W. W., Lackinger, E., and Schiller, D. L., Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody., Lab-Invest, 54, 543-53, 1986.
99. Heddle, J.A., Hite, M., Kirkhart, B., Mavournin, K., MacGregor, J.T., Newell, G.W. and Salamone, M.F. The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 123, 61-118, 1983.
100. Hendrich, S., Glauert, H. P., and Pitot, H. C., The phenotypic stability of altered hepatic foci: effects of withdrawal and subsequent readministration of phenobarbital., Carcinogenesis, 7, 2041-2045, 1986.
101. Hill, R. N., Erdreich, L. S., Paynter, O. E., Roberts, P. A., Rosenthal, S. L., and Wilkinson, C. F., Thyroid follicular cell carcinogenesis., Fundam-Appl-Toxicol, 12, 629-97, 1989.
102. Hisia Y., Oshima M., Kitahori Y., Yuasa T., Fujita T. and Iwata C., Promoting effects of 3-amino-1,2,4-triazole on the development of thyroid tumors in rats treated with N-bis(2-hydroxypropyl)nitrosamine. Carcinogenesis, 3, 381-384, 1982.
103. Holley, A. E., Frater, Y., Gibbs, A. H., De Matteis, F., Lamb, J. H., Farmer, P. B., and Naylor, S., Isolation of two N-monosubstituted protoporphyrins, bearing either the whole drug or a methyl group on the pyrrole nitrogen atom, from liver of mice given griseofulvin., Biochem-J, 274, 843-848, 1991
104. Hoover, R. and Fraumeni, J.F., Drug induced cancer, Cancer, 47 (5), 1071-1080, 1981.
105. Horng, C.B., Bruce, S.A. and Ts'o, P.O., A comparative study on neoplastic transformation of human and Syrian hamster cells, Proc. Natl. Sci. Counc. Rep. China, 9, 255-268, 1985.
106. Hoso, M. and Nakanuma, Cytophotometric DNA-analysis of hepatocellular carcinoma with Mallory bodies, Virch. Arch. A Pathol. Anatomy, 416, 51-55, 1989.
107. Huff, J., Lucier, G. and Tritscher, A., Carcinogenicity of TCDD - experimental, mechanistic, and epidemiologic evidence, Annual Review of Pharmacology and Toxicology, 34, 343-372, 1994.
108. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Some naturally occuring substances, Vol 10, 153-161, 1976.
109. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Suppl. 7, 1987.
110. Ihrig, T.J., Pettit, Akeda, S., Benson, N.C. and French, S.W., Liver injury due to griseofulvin: Gammaglutamyltranspeptidase induction correlated with Mallory bodies. Fed. Proc., 39, 877, 1980.
111. Irie, T., Benson, N.C. and French, S.W., Relationship of Mallory bodies to the cytoskeleton of hepatocytes in griseofulvin treated mice, Lab. Invest., 47, 336-345, 1982.
112. Ito, N., Hananouchi, M., Sugihara, S., Shirai, T., Tsuda, H., Fukushima, S. and Nagasaki, H., Reversibility and irreversibility of liver tumors in mice induced by the alpha isomer of 1,2,3,4,5,6- hexachlorocyclohexane, Cancer Research, 36, 2227-2234, 1976.
113. Jensen, K. and Gluud, C., The Mallory body: morphological, clinical and experimental studies (part 1 of a literature survey), Hepatology, Vol. 20, No. 4, 1061-1077, 1994a.
114. Jensen, K. and Gluud, C., The Mallory body: theories on development and pathological significance (part 2 of a literature survey), Hepatology, Vol. 20, No. 5, 1330-1342, 1994b.
115. Jensen, K. G., Onfelt, A., Poulsen, H.E., Doehmer, J. and Loft, S., Effects of benzo[a]pyrene and (()-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene on mitosis in Chinese hamster V79 cells with stable expression of rat cytochrome P4501A1 or 1A2., Carcinogenesis, 14, 2115-2118, 1993
116. Kappas, A. and Granick, S., Experimental hepatic porphyria. Studies with steroids of physiological origin in man, Am. N.Y. Acad. Sci. 151, 842, 1968.
117. Kappas, A., Sassa, S., Galbraith, R.A. and Nordmann, Y., The porphyrias, In: Scriver, C.R., Baudet, A.L., Sly, W.S. and Valle, D., Eds, The metabolic basis of inherited disease. McGraw-Hill, New York, 1305-1365, 1989.
118. Katsuma, Y., Swierenga, S.H.H., Khettry, U., Marceau, N. and French, S.W., Changes in the cytokeratin intermediate filament cytoskeleton associated with Mallory body formation in mouse and human liver, Hepatology, 7, 1215-1223, 1987.
119. Kerler, R. and Rabes, H.M., Preneoplastic rat liver cells in vitro: Slow progression without promoters, hormones, or growth factors., Journal of Cancer Research and Clinical Oncology, 114, 113-123, 1988.
120. Kimbrough, R.D., Squire, R.A., Linder, R.E., Strandberg, J.D., Montali, J. and Burse, V.W., Introduction of liver tumors in Sherman strain female rats by polychlorinated biphenyl Aroclor 1260., JNCI, 55, 1453-1459, 1975.
121. Kimoff, R. J. and Huang, S., Immunocytochemical and immunoelectron microscopic studies on Mallory bodies., Lab-Invest, 45, 491-503, 1981.
122. Kinsella, A.R., Elimination of metabolic cooperation and the induction of SCEs are not properties common to all promoting or cocarcinogenic agents. Carcinogenesis, 3, 499-504, 1982.
123. Kirby, G. M., Pelkonen, P., Vatanasapt, V., Camus, A. M., Wild, C. P. and Lang, M. A., Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver., MolCarcinog, 11, 81-89, 1994.
124. Klein, M.F. and Beall, J.R., Griseofulvin: a teratogenic study, Science 175, 1483-1484, 1972
125. Klopman, G. and Rosenkranz, H.S., Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity/mutagenicity using MULTICASE, Mutat. Res., 305, 33-46, 1994
126. Klopman, G. and Rosenkranz, H.S., Testing by artificial intelligence: Computational alternatives to the determination of mutagenicity, Mutat. Res., 272, 59-71, 1992
127. Knudson, A. G. Jr., Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68, 820-823, 1971.
128. Kochendörfer, U., Störungen des Zellzyklus durch Anomalien des Spindelapparates. Endogene und exogene Induktion von quantitativen und qualitativen Veränderungen. Doctoral Thesis, Bonn, FRG, 1993.
129. Kociba, R.J., Keyes, D. G., Beyer, J.E., Carreon, R.M., Wade, C.E., Dittenber, D.A., Kalnins, R.P., Frauson, L.E., Park, C. N., Barnard, S.D., Hummel, R.A. and Humiston, C. G., Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats, Toxicol. Appl. Pharmacol., 46, 279-303, 1978.
130. König, E., Berthold, K., Hienz, H.A. and Brittinger, G., Griseofulvin and chronic granulocytic leucemia, Helv. Med. Act., 35, 103-107, 1969.
131. Kordac, V., Martasek, P., Zoubek, V. and Kalab, M., Porphyria cutanea tarda. Manifestation and therapy, Ann. N.Y.Acad.Sci., 514,335-336, 1987
132. Kraupp-Grasl, B., Huber, W., Taper, H., and Schulte-Hermann, R., Increased Susceptibility of Aged Rats to Hepatocarcinogenesis by the Peroxisome Proliferator Nafenopin and the Possible Involvement of Altered Liver Foci Occurring Spontaneously, Cancer Research, 51, 666-671, 1991.
133. Larizza, L., Doneda, L., Colotta, F. and Mantovani, A., Enhanced proliferation and prolonged in vitro life span of human monocytes in conditioned medium from a murine fibrosarcoma line. "Normal and Neoplastic Blood Cells: from Genes to Therapy", Symposium Abstract, 79, 1986
134. Larizza, L., Simoni, G., Stefanini, M. and De Carli, L., Induced heteroploidy and cell transformation, Biochem Exptl. Biol., 12, 433-440, 1976.
135. Larizza, L., Simoni, G., Stefanini, M. and De Carli, L., Spontaneous and griseofulvin-induced segregation for 8-azaguanine resistance in hybrids from a human heteroploid line, Exp. Cell Res., 120, 405-409, 1979.
136. Larizza, L., Simoni, G., Tredici, F. and De Carli, L., Griseofulvin: a potential agent of chromosomal segregation in cultured cells., Mutat-Res, 25, 123-30, 1974.
137. Latt, S. A., Sister chromatid exchange formation., Annu-Rev-Genet, 15, 11-55, 1981.
138. Leonard, A., Poncelet, F., Grutman, G., Carbonelle, E. and Fabry, L., Mutagenicity tests with griseofulvin, Mutat. Res., 68, 225-234, 1979.
139. Levine, A. J., Momand, J. and Finlay, C. A., The p53 tumour suppressor gene., Nature, 351, 453-6, 1991.
140. Li, J.J., Gonzalez, A., Banerjee, S., Banerjee, S.K. and Li, S.A., Estrogen carcinogenesis in the hamster kidney: role of cytotoxicity and cell proliferation., Environm. Health Perspect, 101 Suppl 5, 259-64, 1993
141. Lin, C.C., Chang, R., Casmer, C., Symchowicz, S , Effects of phenobarbital, 3-methylcholanthrene and griseofulvin on the o-demethylation of griseofulvin by liver microsomes of rats and mice, Drug. Metabol. Disp., 1, 611-618, 1973a.
142. 14C-griseofulvin in man, J. Pharmacol. Exptl. Ther., 187, 415-422, 1973b.
143. Lin, C.C. and Symchowicz, S., Absorption, distribution, metabolism and excretion of griseofulvin in man and animals. Drug Metabol. Rev., 4(1), 75-95, 1975.
144. Linnik, A.B., Experimental study on the possible role of griseofulvin in carcinogenesis, Vestn. Derm. Vener., 46, 49-51, 1972.
145. Lithner, F. and Wetterberg, L., Hepatocellular carcinoma in patients with acute intermittent porphyria, Acta. Med. Scand., 215, 271-274, 1984.
146. Lo Schiavo, F., Nuti Ronchi, V. and Terzi, M., Genetic effects of griseofulvin on plant cell cultures, Theor. Appl. Genet., 58, 43-47, 1980.
147. Lowe, J., Blanchard, A., Morrell, K., Lennox, G., Reynolds, L., Billett, M., Landon, M., and Mayer, R. J., Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease., J-Pathol, 155, 9-15, 1988
148. MacLeod, J. and Nelson, W.O., Griseofulvin and human spermatogenesis, Proc. Soc. Exp. Med. Biol., 102, 259-260, 1960.
149. Mailhes, J.B., Marchetti, F. and Aardema, M.J., Griseofulvin induced aneuploidy and meiotic delay in mouse oocytes: effects of dose and harvest time, Mutat. Res. 300, 155-163, 1993.
150. Mallory, F.B., Cirrhosis of the liver: five different lesions from which it may arise, Bull. John Hopkins Hosp., 22, 69, 1911.
151. Marchetti, F. and Mailhes, J.B., Variation of mouse oocyte sensitivity to griseofulvin induced aneuploidy during the first meiotic division, Env. Molec. Mutagen. 23, 179-185, 1994.
152. Marchetti, F., Mailhes, J.B., Variation of mouse oocyte sensitivity to griseofulvin induced aneuploidy during the second meiotic division, Mutagenesis 10, 113-121, 1995.
153. Marks, G. S., Powles, J., Lyon, M., McCluskey, S., Sutherland, E. and Zelt, D., Patterns of porphyrin accumulation in response to xenobiotics. Parallels between results in chick embryo and rodents., Ann. N,-Y.Acad.Sci, 514, 113-27, 1987.
154. Marvel, J.R., Schlichting, D.A., Denton, C., Levy, E.J. and Cahn, M.M., The effect of surfactant and of particle size on griseofulvin plasma levels, J. Invest. Dermatol., 142, 197-203, 1964.
155. Matilla, A. and Molland, E.A., A light and electron microscopic study of the liver in case of erythrohepatic protoporphyria and in griseofulvin-induced porphyria in mice, J. Clin. Pathol., 27, 698-709, 1974.
156. McClain, The signifiance of hepatic microsomal enzyme induction and altered enyzyme function in rats: implications for thyroid gland neoplasia. Toxic Pathology, 17, 294-306, 1989.
157. McIntosh, D.A.D. and Topham, J.C., A comparison of mouse and rat liver enzymes and their response to treatment with various compounds, Biochem. Pharmacol. 21, 1025-1029, 1972.
158. MacLeod, J. and Nelson, W.O., Griseofulvin and human spermatogenesis, Proc. Soc. Exp. Med. and Biology, 102, 259-260, 1960.
159. Medoff, G. and Kobayashi, G., Mode of action of antifungal drugs. VII. Griseofulvin, in Fungi Pathogenic for Humans and Animals. Part B. Pathogenicity and Detection. Howard, D.H., Ed., Marcel Dekker Inc., N.Y., 1983, 345-355.
160. Meierhenry, E.F., Ruebner, B.H., Gershwin, M.E., Hsieh, L.S. and French, S.W., Mallory body formation in hepatic nodules of mice ingesting dieldrin, Lab. Invest., 44, 392-396, 1981.
161. Melnick, R.L., Does chemically induced hepatocyte proliferation predict liver carcinogenesis, FASEB Journal, 6, 2698-2706, 1992.
162. Metneki, J. and Czeizel, A., Griseofulvin teratology, The Lancet, May 2, 1042, 1987.
163. Morris H.P., The experimental development and metabolism of thyroid gland tumors. Adv. Cancer Res., 3, 51-115, 1955.
164. Muccinelli, A. and Sanguinetti, F., [Effect of the administration of copper salts on cholesteremia and beta-lipoproteinemia in rats treated with griseofulvin], Boll-Soc-Ital-Biol-Sper, 43, 1651-2, 1967.
165. Nagasaki, H., Tomii, S., Mega, T., Marugami, M. and Ito, N., Hepatocarcinogenicity of polychlorinated biphenyls in mice., GANN, 63, 805, 1972.
166. Nakanuma, Y. and Ohta, G., Is mallory body formation a preneoplastic change? A study of 181 cases of liver bearing hepatocellular carcinoma and 82 cases of cirrhosis, Cancer 55, 2400-2404, 1985.
167. Nakao, K., Wada, O., Takaku, F., Sassa, S., Yamo, Y. and Urata, G., The origin of the increased protoporphyria in erythrocytes of mice with experimentally induced porphyria, J. Lab. Clin. Med., 70, 923-932, 1967.
168. Namba, M. and Kimoto, T., Cytotoxic effects of griseofulvin on human normal cells in vitro. Kawasaki Med. J., 2, 127-134, 1976.
169. Navone, N. M., Buzaleh, A. M., Polo, C. F., Afonso, S. G., Vazquez, E. S. and Batlle, A. M., The effect of griseofulvin on the heme pathway - II. An exhaustive analysis during short and long-term challenge., Gen-Pharmacol, 22, 1179-83, 1991.
170. Ohmori, T., Rice, J. M., and Williams, G. M., Histochemical characteristics of spontaneous and chemically induced hepatocellular neoplasms in mice and the development of neoplasms with gamma-glutamyl transpeptidase activity during phenobarbital exposure., Histochem-J, 13, 85-99, 1981.
171. Ohshima, H. and Bartsch, H., Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis., Mutat-Res, 305, 253-64, 1994.
172. Okino, K. and Weibert, R.T., Warfarin-Griseofulvin interaction. Drug. Intell. Clin. Pharm. 20, 291-294, 1986.
173. Oshimura, M. and Barrett, J.C., Chemically induced aneuploidy in mammalian cells: Mechanisms and biological significance in cancer, Env. Mutagen, 8, 129-159, 1986.
174. Otto, A.M., Ulrich, M.O., Zombe, A. and Jimenez de Asua, L., Microtubule disrupting agents affect two different events regulating the initiation of DNA-synthesis in Swiss 3T3 cells, Proc. Natl. Acad. Sci. U.S.A., 78(5), 3063-3067, 1981.
175. Oxford, A.E., Raistrick, H. and Simonart, P., Griseofulvin - a metabolic product of Penicilium griseofulvum dierckx., Biochem. J., 33, 240-248, 1939.
176. Paget, G.E. and Alcock, S.J., Griseofulvin and colchicine: Lack of carcinogenic action, Nature, 188, 867, 1960.
177. Paget, G.E. and Walpole, A.L., Some cytological effects of griseofulvin, Nature, 182, 1320-1321, 1958.
178. Parzefall, W., Schuppler, J., Barthel, G., Meyer Rogge, B., and Schulte Hermann, R., Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver., Toxicol-Appl-Pharmacol, 106, 482-99, 1990.
179. Peters, R.S., Patology of hepatocellular carcinoma, in Hepatocellular Carcinoma, Okuda, K., and Peters, R., Eds., N.Y. Wiley & Sons, 1976, 107-168.
180. Pierach, C.A., Porphyria and hepatocellular carcinoma, Brit. J. Canc., 59, 111, 1987.
181. Pitot, H.C., Progression - the terminal stage in carcinogenesis, Japanese Journal of Cancer Research, 80, 599-607, 1989
182. Poland, A. and Knudson, J.C., 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity, Annual Review of Pharmacology and Toxicology, 22, 517-554, 1982.
183. Preisegger, K. H., Stumptner, C., Riegelnegg, D., Brown, P. C., Silverman, J. A., Thorgeirsson, S. S., and Denk, H., Experimental Mallory body formation is accompanied by modulation of the expression of multidrug-resistance genes and their products., Hepatology, 24, 248-52, 1996
184. Preisegger, K. H., Zatloukal, K., Spurej, G., Riegelnegg, D., and Denk, H., Common epitopes of human and murine Mallory bodies and Lewy bodies as revealed by a neurofilament antibody., Lab-Invest, 66, 193-9, 1992
185. Raimondi, E., Scariolo, S., De Sario, A. and De Carli, L., Aneuploidy assays on interphase nuclei by means of in situ hybridisation with DNA-probes, Mutagenesis, 4, 165-169, 1989.
186. Rao, K. N., The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis (review)., Anticancer-Res, 15, 309-14, 1995.
187. Redeker, A. G., Sterling, R.E. and Bronow, R.S., Effect of griseofulvin in acute intermittent porphyria, J. Am. Med. Assoc, 188, 466-468, 1964.
188. Rimington, C., Morgan, P. N., Nicholls, K., Everall, J.D. and Davies, R.R., Griseofulvin administration and porphyrin metabolism, Lancet, Aug 17, 318-322, 1963.
189. Rijhsinghani, K. S., Abrahams, C., Swerdlow, M. A., Rao, K. V., and Ghose, T., Induction of neoplastic lesions in the livers of C57BL x C3HF1 mice by chloral hydrate., Cancer-Detect-Prev, 9, 279-88, 1986.
190. Roobol, A. Gull, K. and Pogson, C.J., Inhibition by griseofulvin of microtubule assembly in vitro, FEBS. Lett., 67, 248-251, 1976.
191. Rosa, F.W., Hernandez, G. and Carlo, W.A., Griseofulvin teratology including two thoracopagus conjoined twins, Lancet, 1(8525), 171, 1987.
192. Rosin, H., Antibiotika and Chemotherapeutika. Antiinfektiöse Therapie, in Allgemeine und spezielle Pharmakologie und Toxikologie, Forth, W., Henschler, D., Rummel, W., Starke, K., Eds., BI-Wissenschaftsverlag, 1992, 687-688.
193. Rowland, M., Riegelman, S. and Epstein, W.L., Absorption kinetics of griseofulvin in man, J. Pharmaceut. Sci., 57, 984-989, 1968.
194. Rozengurt, R., Growth factors, cell proliferation and cancer: an overview, Mol. Biol. Med., 1, 169-181, 1983.
195. Rubin, A. and Dvornik, D., Placental transfer of griseofulvin, Amer. J. Obstet. Gynec. 92, 882-883, 1965.
196. Russel, D. and Russel, A.D., Treatment of ringworm: old remedy vesus new, J. Infect. 24, 333, 1992.
197. Rustia, M. and Shubik, P., Thyroid tumors in rats and hepatomas in mice after griseofulvin treatment, Br. J. Canc., 38, 237-249, 1978.
198. Salonpää P., Krause K., Pelkonen O. and Raunio H., Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn-Schmiedebergs Arch. Pharmacol., 351, 446-452, 1995.
199. Sandow J. and Rechberg W., Griseofulvin: Subchronische orale Verträglichkeitsprüfung. Höchst Report, No. 891571, 1990.
200. Schiffmann, D. and De Boni, U., Dislocation of chromatin elements in prophase induced by diethylstilbestrol: a novel mechanism by which micronuclei can arise., Mutat. Res, 246, 113-22, 1991
201. Schmaehl, D., Iatrogenic carcinogenesis, J. Canc. Res. Clin. Oncol., 99, 71-75, 1981.
202. Schulte-Hermann, R., Induction of liver growth by xenobiotic compounds and other stimuli., Critical Rev. Toxicol., 3, 97-158, 1974.
203. Schulte-Hermann, R., Tumor promotion in the liver., Arch. Toxicology, 57, 147-158, 1985.
204. Schulte-Hermann, R., Bursch, W., Kraupp-Grasl, B., Oberhammer, F., Wagner, A., and Jirtle, R., Cell proliferation and apoptosis in normal liver and preneoplastic foci, Environmental Health Perspectives, 101, 87-90, 1993.
205. Schulte-Hermann, R., Ohde, G., Schuppler, J. and Timmermann Trosiener, I., Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin., Cancer Res., 41, 2556-2562, 1981.
206. Schulte-Hermann, R., Timmermann-Trosiener, I. and Schuppler, J., Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds., Cancer Res., 43, 839-844, 1983.
207. Schulte-Hermann, R., Timmermann-Trosiener, I., Barthel, G. and Bursch, W., DNA synthesis, apoptosis and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion., Cancer Research, 50, 5127-5135, 1990.
208. Scott, F.W., LaHunta, A., Schultz, R.D., Birkner, S.I. and Riis, R.C., Teratogenesis in cats, associated with griseofulvin therapy, Teratology, 2, 79-86, 1975.
209. Seglen, P.O. and Gerlyng, P., Growth-related alterations during liver carcinogenesis - effect of promoters, Environmental Health Perspectives, 88, 197-205, 1990.
210. Seif, R., Factors which disorganize microtubules or microfilaments increase the frequency of cell transformation by polyoma virus, J. Virol., 36, 421-428, 1980.
211. Sewall, C. H., Flagler, N., Vanden Heuvel, J. P., Clark, G. C., Tritscher, A. M., Maronpot, R. M., and Lucier, G. W., Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin., Toxicol-Appl-Pharmacol, 132, 237-44, 1995.
212. Shah, V.P., Griseofulvin - absorption per os and percutaneous, Medical Mycology Zbl. Bact., Suppl. 8, 223-239. 1980.
213. Shimoyama, T. and Nonaka, S., Biochemical studies on griseofulvin induced protoporphyria, Ann. NY. Acad. Sci., 514, 160-169, 1987.
214. Shimoyama, T., Nonaka, S., Honda, T., Murayama, F., Ohgami, T. and Yoshida, H., A biochemical study on experimental porphyria I. The influence of griseofulvin at various concentrations on porphyrin metabolism, J. Dermatol., 11, 49-55, 1984.
215. Sideropoulos, A.S., Kacsuta, P. and Betz, M.K., Mutations induced by substituted quinolines in UV-irradiated bacteria, Current Microbiol., 3, 207-212, 1980.
216. Siracusa G., Whittigham D. G. and DeFelici M., The effect of microtubule and microfilament disrupting drugs on preimplantation mouse embryos. J. Embr. Exp. Morph., 60, 71-82, 1980
217. Slonitskaya, N. N. and Mikhailets, Embryotoxic and teratogenic effects of isogriseofulvin-forte at various stages of rat embryogenesis, Antibiotiki 18, 655-659, 1973.
218. Slonitskaya, N. N., Teratogenic effects of griseofulvin-forte on rat fetus, Antibiotiki 11, 44-48, 1969.
219. Smith, A. G. and De Matteis, F., Drugs and the hepatic porphyrias., Clin-Haematol, 9, 399-425, 1980.
220. Smith, A. G., Francis, J.E., Dinsdale, D., Manson, M.M. and Cabral, J.R.P., Hepatocarcinogenicity of hexachlorobenzene in rats and sex difference in hepatic iron states and development of porphyria, Carcinogenesis, 6, 631-636, 1985.
221. Smith, A. G., Francis, J.E., Green, J.A., Greig, J.B., Wolf, C.R. and Manson, M.M., Sex-linked hepatic uroporphyria and the induction of cytochromes P450IA in rats caused by hexachlorobenzene and polyhalogenated biphenyls., Biochem. Pharmacol, 40, 2059-68, 1990.
222. Steelman, L.R. and Kocsis, J.J., Determination of the teratogenic and mutagenic potential of griseofulvin, Toxicol. Appl. Pharmacol. 45, 343-344, 1978.
223. Stolley, P.D., Drugs and cancer in humans, Preventive Med., 9, 202-205, 1980.
224. Stout, D.L. and Becker, F.F., Heme enzyme patterns in rat liver nodules and tumors, Canc. Res., 47, 963-965, 1987.
225. Symchowicz, S. and Katchen, B., Griseofulvin absorption in man after single and repeated treatment and its correlation with dissolution rates, J. Pharmaceut. Sci., 57, 1383-1386, 1968.
226. Tanaka K., Ohgami T. and Nonaka S., Experimental murine protoporphyria induced by griseofulvin: The relationship between hepatic porphyrin levels and liver function test values in mice treated with griseofulvin J.Dermatol., 20, 545-553, 1993
227. Tangeras, A., Effect of decreased ferrochelatase activity on iron and porphyrin content in mitochondria of mice with porphyria induced by griseofulvin, Biochim. Biophys. Acta, 882, 77-84, 1986.
228. Tazawa, J., Ihrig, T. and French, S.W., Mallory body formation runs parallel to gamma-glutamyl transferase induction in hepatocytes of griseofulvin mice. Hepatology, 3, 989-1001, 1983.
229. Terzi, M. and Hawkins, T.S.C., Chromosomal variation and the establishment of somatic cell lines in vitro, Nature, 253, 361-362, 1975.
230. Thomsett, L.R., Fungal diseases of the skin of small animals, Brit. Vet. J., 142, 317-325, 1986.
231. Tiveron, C., Marchetti, F., Bossoni, B. and Pacchierotti, F., Griseofulvin induced aneuploidy and meiotic delay in female mouse germ cells, I. Cytogenetic analysis of metaphase II oocytes, Mutat. Res.,266, 143-150, 1992.
232. Topham, J. C., McIntosh, D. A., and Platt, D. S., Biochemical changes in rat liver in response to treatment with drugs and other agents. IV., BiochemPharmacol, 21, 1019-24, 1972
233. Tsunoo, C., Harwood, T. R., Arak, S., and Yokoo, H., Cytoskeletal alterations leading to Mallory body formation in livers of mice fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine., J-Hepatol, 5, 85-97, 1987
234. Udall, J.A. .Drug interference with warfarin therapy. Clinical Medicine, 77, 20-25, 1970.
235. Van Heyningen, V. and Hastie, N. D., Wilms' tumour: reconciling genetics and biology., Trends in Genet, 8, 16-21, 1992.
236. Vesselinovitch, S.D. and Mikailovitch, N., The inhibitory effect of griseofulvin on the promotion of skin carcinogenesis, Canc. Res., 28, 2463-2465, 1968.
237. Wada, O., Toyokawa, K., Urata, G., Yano, Y., and Nakao, K., Cholesterol biosynthesis in the liver of experimentally induced porphyric mice., BiochemPharmacol, 18, 1533-5, 1969.
238. Wada, O., Yano, Y., Urata, G. and Nakao, K., Behaviour of hepatic cytochromes after treatment of mice with drugs known to disturb porphyrin metabolism in liver, Biochem. Pharmacol., 17, 595-603, 1968.
239. Wang, A. and Rozengurt, E., Interplay of cyclic AMP and microtubules in modulating the initiation of DNA synthesis in 3T3 cells. J. Cell Biol., 96, 1743-1750, 1983
240. Wastl, U. M., Lang, M. A., Bursch, W., Camus-Randon, A. M., and Schulte-Hermann, R., Expression of cytochrome P450 2A5 in normal liver, preneoplastic foci and liver tumors of different mouse strains, Toxicol. Appl. Pharmacol. (submitted).
241. Watson, C.J. Lynch, F., Bossenmaier, I. and Cardinal, R., Griseofulvin and porphyrin metabolism, Arch. Derm., 98, 451-468, 1968.
242. Wehland, I., Herzog, W. and Weber, K., Interaction of griseofulvin with microtubules, microtubuli protein and tubulin, J. Molec. Biol., 111, 329-342, 1977.
243. Weinberg R.A., Tumor suppressors genes, Science, 254, 1138-1146, 1991.
244. Weston-Hurst, E. and Paget, G.E., Protoporphyrin, cirrhosis and hepatomata in the livers of mice given griseofulvin, Brit J. Derm., 75, 105-112, 1963.
245. Wetzl, W.J. and Alexander, R.W., Fowl nodular hyperplasia of the liver with alcoholic hyaline bodies and cytologic atypia, Cancer 44, 1322-1326, 1979.
246. Whittaker, S. G., Wilson, D. and Faustmann, Griseofulvin and estramustine induce mitotic arrest in rat embryonic limb bud cultures, Toxicologist 13, 257, 1993.
247. Whittaker, S. G., Zimmermann, F.K., Dicus, B., Piegorsch, W.W., Fogel, S. and Resnick, M.A., Detection of induced mitotic chromosome loss in Saccharomyces cervisiae - an interlaboratory study, Mutat. Res., 224, 31-78, 1989.
248. Williams, G. M., Ohmori, T., Katayama, S., and Rice, J. M., Alteration by phenobarbital of membrane-associatedenzymes including gamm glutamyl transpeptidase in mouse liver neoplasms, Carcinogenesis, 1, 813-818, 1980.
249. Williams, M. T. and Simonet, L., Effects of griseofulvin on enzymes associated with phase I and II of drug metabolism., Biochem-Pharmacol, 35, 2630-2632, 1986.
250. Wilson, L., Bamburg, J.R., Mizel, S.B., Grisham, L.M. and Creswell, K.M, Interaction of drugs with microtubuli proteins, Fed. Proc., 33, 158-166, 1974
251. Winterhoff H. and Sourgens H., The predictive value of animal experiments in the detection of side effects of drugs on thyroid function. Pharmac.Ther. 5, 325-332, 1979
252. Wong, P.T.T., Cadrin, M. and French, S.W., Distinctive infrared spectra features in liver tumor tissue of mice: Evidence of structural modifications at the molecular level. Exp. Molec. Pathol., 55, 269-284, 1991.
253. Wyrobek, A.J. and Bruce, W.R., Chemical induction of sperm abnormalities in mice, Proc. Natl. Acad. Sci. USA 72, 4425-4429, 1975.
254. Wyrobek, A.J. and Bruce, W.R., The induction of sperm-shape abnormalities in mice and humans, in Chemical Mutagens - Principles and Methods for their Detection, Hollaender, A., Ed.,Vol VII, 1982, 257-285,.
255. Xu, G. F., O'Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R. and White, R. The neurofibromatosis type 1 gene encodes a protein related to GAP., Cell, 62, 599-608, 1990.
256. Yager, J.D., Zurlo, J. and Nan, N., Sex hormones and tumor promotion in liver, Proc. Soc. Exp. Biol. Med., 667-674, 1991.
257. Yokoo, H., Craig, R.M., Harwood, T.R. and Cochrone, C., Griseofulvin-induced cholestasis in Swiss Albino mice, Gastroenterology, 77, 1082-1087, 1979.
258. Yokoo, H., Harwood, T. R., Racker, D., and Arak, S., Experimental production of Mallory bodies in mice by diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine., Gastroenterology, 83, 109-13, 1982
259. Zatloukal, K., Denk, H., Lackinger, E., and Rainer, I., Hepatocellular cytokeratins as substrates of transglutaminases., Lab-Invest, 61, 603-8, 1989
260. Zatloukal, K., Denk, H., Spurej, G., Lackinger, E., Preisegger, K. H., and Franke, W. W., High molecular weight component of Mallory bodies detected by a monoclonal antibody., Lab-Invest, 62, 427-34, 1990
261. Zawirska, B. and Bednarz, W., The particular trais of carcinogenesis induced in wister rats by Aflatoxin B1, III, Porphyrins and the activity of gamma-glutamyl-transpeptidase in hepatomas and in their tissue of origin, Neoplasma 28, 35-49, 1981.
262. Zbinden G. Hyperplastic and neoplastic responses of the thyroid gland in toxicological studies. Arch.Toxicol. Suppl. 12, 98-106, 1988.
263. Zhang, Y. P., Sussman, N., Macina, O. T., Rosenkranz, H. S., and Klopman, G., Prediction of the carcinogenicity of a second group of organic chemicals undergoing carcinogenicity testing, Environmental Health Perspectives, 104 Suppl 5, 1045-1050, 1996.